'Second wave' of Covid infections impacting business normalization: Nomura

Coronavirus infections are rising in Maharashtra and other states

experts, business, conference
Representative image. Photo: Shutterstock
Press Trust of India Mumbai
2 min read Last Updated : Mar 22 2021 | 8:16 PM IST

The 'second wave' of the pandemic is delaying business normalization in the country, as coronavirus infections rise in Maharashtra and other states, a report by a Japanese brokerage said on Monday.

The Nomura India Business Resumption Index dipped to 95.1 for the week to March 21 from 95.4 in the previous week as a result of the rising infections, the brokerage said.

COVID-19 infections are rising to new heights across the country and many local governments have been forced to re-introduce stricter measures like night-time curfews and sealing off premises in order to contain the spread.

The pandemic's second wave is now spreading to states outside Maharashtra and is starting to impact mobility. This suggests a likely sequential dip in contact-based services and a near-term delay of normalization, it said.

The brokerage added that it expects the impact to be more transitory and muted, as factory operations remain uninterrupted, consumers and businesses have adapted to the new normal and medium-term tailwinds like vaccinations, global growth, easy financial conditions continue.

It said as of mid-March, Google workplace and retail and recreation mobility fell by 3.7 percentage points on a week-on-week basis and 0.3 percentage points, respectively, while the more updated Apple driving index fell by 2.6 percentage points.

However, power demand improved by 2.6 per cent week-on-week after a 0.6 per cent decline the prior week, while the labour participation rate inched up to 40.6 per cent from 39.5 per cent.

The knock-on effect of the second wave on mobility suggests a likely sequential dip in contact-based services and a near-term delay of normalization, it said.

The medium-term tailwinds from the lagged impact of easy financial conditions, fiscal activism, strong global growth and continuing vaccine momentum will support real GDP growth of 13.5 per cent in FY22, up from a contraction of 7.4 per cent in FY21, it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Mar 22 2021 | 8:06 PM IST

Next Story